Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relative Bioavailability of Empagliflozin Tablets After Different Administration Modi in Healthy Male and Female Subjects (Randomised, Two-period Crossover Study)

Trial Profile

Relative Bioavailability of Empagliflozin Tablets After Different Administration Modi in Healthy Male and Female Subjects (Randomised, Two-period Crossover Study)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Acute heart failure; Cardiovascular disorders; Chronic heart failure; Decompensated heart failure; Gestational diabetes; Heart failure; Insulin resistance; Kidney disorders; Renal failure; Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 18 Sep 2025 Status changed from active, no longer recruiting to completed.
  • 29 Aug 2025 Planned End Date changed from 7 Jul 2025 to 14 Sep 2025.
  • 05 Aug 2025 Planned End Date changed from 30 Jun 2025 to 7 Jul 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top